Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma

. 2010 May ; 456 (5) : 463-72. [epub] 20100420

Jazyk angličtina Země Německo Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid20405298

Childhood rhabdomyosarcoma (RMS) has two major histological subtypes: alveolar (aRMS) and embryonal. The aim of the study was to monitor minimal disseminated disease (MDD) using real-time quantitative reverse-transcription PCR (RQ-RT-PCR) of the PAX3-FKHR, PAX7-FKHR fusion genes and myoD1 gene. We prepared an assay using RQ-RT-PCR for a quantitative assessment of MDD in aRMS by using hydrolysis probe for quantification of PAX3-FKHR, PAX7-FKHR and myoD1 genes and beta-2-microglobulin housekeeping gene. Primary tumor samples (44), samples of local recurrences (26) from 48 patients with aRMS were examined by nested RT-PCR and RQ-RT-PCR techniques. Additionally, bone marrow samples (115), peripheral blood progenitor cell samples (27), and peripheral blood samples (25) from 33 aRMS patients were tested. PAX3/7-FKHR and myoD1 transcripts proved to be a sensitive tool for detection of MDD in RMS. We were able to identify 15/25 patients with bone marrow (BM) involvement at the time of presentation using RQ-RT-PCR. We analyzed PAX3-FKHR or PAX7-FKHR expression during the course of the disease. The RQ-RT-PCR results correlated well with nested RT-PCR results (p < 0.0001). The presence of metastases is the most adverse prognostic factor in RMS, and bone marrow is a frequent site of the tumor dissemination in RMS, especially in aRMS. Our results detecting the fusion transcripts or myoD1 transcript in the BM or peripheral blood suggest that patients with positive findings are at high risk of the tumor progression.

Zobrazit více v PubMed

Prog Clin Biol Res. 1988;271:91-101 PubMed

Curr Top Pathol. 1995;89:241-59 PubMed

J Mol Diagn. 1999 Nov;1(1):23-31 PubMed

Am J Pathol. 1998 Feb;152(2):577-83 PubMed

Cancer. 1996 Sep 15;78(6):1320-7 PubMed

Bone Marrow Transplant. 1999 Sep;24(5):527-33 PubMed

Cancer. 2006 Apr 15;106(8):1766-75 PubMed

Diagn Mol Pathol. 2000 Mar;9(1):9-13 PubMed

Med Pediatr Oncol. 2003 Jan;40(1):1-8 PubMed

J Clin Oncol. 2003 Jan 1;21(1):85-91 PubMed

Virchows Arch. 2006 Apr;448(4):449-58 PubMed

Cancer Res. 2006 Jul 15;66(14):6936-46 PubMed

Cancer. 1993 Mar 1;71(5):1904-22 PubMed

Cancer. 1984 Jan 15;53(2):368-73 PubMed

Clin Chem. 2001 Feb;47(2):195-201 PubMed

J Pediatr Hematol Oncol. 2001 Feb;23(2):99-104 PubMed

J Clin Oncol. 2004 May 15;22(10):1902-8 PubMed

J Cancer Res Clin Oncol. 2006 Jun;132(6):356-62 PubMed

Eur J Cancer. 2005 Oct;41(15):2288-96 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...